Pomerantz Law Firm Launches Investigation into Novo Nordisk A/S for Potential Investor Claims Pomerantz LLP is conducting an investigation regarding potential securities fraud claims against Novo Nordisk A/S, following disappointing trial results of CagriSema.

Pomerantz Law Firm Launches Investigation into Novo Nordisk A/S for Potential Investor Claims #USA #New_York #Pomerantz_LLP #Novo_Nordisk #CagriSema

Toplines from a non-inferiority trial of #CagriSema vs #tirzepatide were another tough break for @novonordisk.bsky.social yesterday. We will have to wait and see what the true clinical value for this combination therapy will be. But it's unlikely to be a home run.
conscienhealth.org/2026/02/24/c...

Head-to-head trial dents Novo Nordisk's obesity hopes Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

#NovoNordisk's new two-drug combination for #weightloss, #CagriSema, performed worse than Eli Lilly's rival Zepbound in a #comparativetrial, putting further pressure on its stock.

¿Qué falló en CagriSema y hundió a Novo Nordisk en Bolsa? Novo Nordisk se hunde en Bolsa por CagriSema: el ensayo clave frente a tirzepatida decepciona y refuerza a Eli Lilly, cifras y consecuencias. Novo Nordisk se dejó en el parqué una parte notable de su ...

¿Qué falló en CagriSema y hundió a Novo Nordisk en Bolsa? #NovoNordisk #EliLilly #CagriSema #Tirzepatida #Wegovy #Ozempic #Zepbound #Mounjaro #Obesidad #Farmaceuticas #Bolsa #Mercados #23defebrero #felizlunes donporque.com/novo-nordisk...

Experience a metabolic breakthrough with the Ultima-Cagri+Sema Blend 5mg+5mg, now available at OSGear.to. This elite formulation from Ultima Peptides – US merges Semaglutide and Cagrilintide to attack weight loss from two angles. While Semaglutide optimizes insulin and curbs cravings, Cagrilintide acts as a potent Amylin agonist to prolong fullness and slow digestion. This synergistic approach offers superior results compared to standalone therapies, promoting significant body weight reduction and improved A1C levels. Each high-purity vial is manufactured in the USA, ensuring pharmaceutical-grade quality for your wellness journey. Secure the most advanced once-weekly metabolic tool today and transform your physique with precision.

Double the power, double the results! 💥 The Ultima-Cagri+Sema Blend (5mg+5mg) is now at OSGear.to. Combining Semaglutide & Cagrilintide, it’s the ultimate duo for appetite control and fat loss. 🚀
Shop: osgear.to/product/ulti...

#CagriSema #WeightLoss #OSGear #Fitness #UltimaCagriSemaBlend

Novo Nordisk's CagriSema tops Ozempic in diabetes trial Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study

#NovoNordisk is considering filing #CagriSema for diabetes, in addition to #obesity, after it outperformed #Ozempic in a head-to-head study.

pharmaphorum.com/news/novo-no...

#CagriSema #NVO

Novo Nordisk Seeks FDA Approval for Innovative Obesity Treatment, CagriSema Novo Nordisk has filed for FDA approval of CagriSema, a groundbreaking weekly treatment combining GLP-1 and amylin analogues for effective weight management.

Novo Nordisk Seeks FDA Approval for Innovative Obesity Treatment, CagriSema #USA #Novo_Nordisk #Plainsboro #Obesity_Treatment #CagriSema

Novo Nordisk Seeks FDA Approval for CagriSema: A Breakthrough in Weight Management Novo Nordisk has submitted an NDA for CagriSema, an innovative weekly injection combining GLP-1 and amylin analogues for weight loss.

Novo Nordisk Seeks FDA Approval for CagriSema: A Breakthrough in Weight Management #USA #Semaglutide #Novo_Nordisk #Plainsboro #CagriSema

ObesityWeek 2025: Game-Changing Innovations in Obesity Treatments Revealed ObesityWeek 2025 unveiled groundbreaking data on obesity treatments, showcasing advances in therapies and a shift toward personalized medicine in combating obesity.

ObesityWeek 2025: Game-Changing Innovations in Obesity Treatments Revealed #United_States #Atlanta #Eli_Lilly #CagriSema #ObesityWeek

Novo Nordisk's CagriSema Clinically Lowers Blood Pressure and Reduces Heart Disease Risk Novo Nordisk's CagriSema demonstrates significant blood pressure reduction and anti-inflammatory benefits in patients at ObesityWeek® 2025.

Novo Nordisk's CagriSema Clinically Lowers Blood Pressure and Reduces Heart Disease Risk #United_States #Atlanta #obesity #Novo_Nordisk #CagriSema

Novo Nordisk's CagriSema: Promising Outcomes in Cardiovascular Health at ObesityWeek Novo Nordisk's CagriSema shows significant cardiovascular health improvement, including blood pressure reduction and anti-inflammatory effects in new analyses presented at ObesityWeek.

Novo Nordisk's CagriSema: Promising Outcomes in Cardiovascular Health at ObesityWeek #USA #Atlanta #Novo_Nordisk #CagriSema #ObesityWeek

Novo Nordisk Unveils New Insights on Oral Semaglutide at ObesityWeek 2025 Novo Nordisk is set to share groundbreaking data on oral semaglutide 25 mg at ObesityWeek 2025, showcasing significant findings on obesity treatments.

Novo Nordisk Unveils New Insights on Oral Semaglutide at ObesityWeek 2025 #United_States #Atlanta #Novo_Nordisk #Wegovy #CagriSema

CagriSema Elicits Significant Weight Loss in Obesity With or Without T2D CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

Once-weekly #CagriSema vs placebo improves weight loss among adults who have overweight or #obesity with or without #T2D.

Read More: https://bit.ly/4mcSqPM

A new editorial in @nejm.org has us thinking that analysts who dismiss outcomes with #CagriSema and #orforglipron are missing a big shift in goals for obesity treatment. Long-term health is becoming more important than short-term weight loss alone.
conscienhealth.org/2025/08/targ...

✨New issue!✨

🧪

Check out the latest in #metabolism research from across all disciplines.

Read about #Triglycerides in the #Brain, #CagriSema, #Exercise, #LipidMetabolism, the #Microbiome - and many more topics!

www.nature.com/natmetab/vol...

The Obesity Drug Chessboard after ADA2025 with Q2 Earnings in Play ♟️ - MidgardFinance.com Quick status check on Novo, Lilly, and rivals after ADA 2025 – just ahead of Q2 earnings. Introduction Novo Nordisk and Eli Lilly will release their Q2 results on 6 and 7 August.ADA 2025, which wrappe...

♟️ ADA 2025 reshuffled the obesity-drug board. Q2 earnings will redeploy the pieces Aug 6-7. Time to see which ones rise and which fall.
blog.midgardfinance.com/2025/07/21/t...

#Amycretin #Orforglipron #Retatrutide #CagriSema #Bimagrumab #Semaglutide #Wegovy #Zepbound
#NOVO-B.CO #LLY.US #NVO #LLY

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk (NYSE:NVO) fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly (NYSE:LLY)’s pipeline. Novo on Sunday said full results from two late-stage trials of CagriSema - one in people with obesity or overweight, the other in overweight type 2 diabetics - showed mainly mild-to-moderate side effects and positive outcomes on blood sugar. But, as analysts had predicted ahead of the data release, investors remained sceptical. Jefferies called the updates "incremental" and flagged concerns over tolerability, as CagriSema caused slightly more nausea than both Novo’s blockbuster obesity injection Wegovy and Lilly’s rival therapy Zepbound. The drug is not expected to launch until early 2027, "a long time interval for investors", Novo and Lilly shareholder Markus Manns told Reuters. Manns said sentiment in Lilly had been buoyed by data it also presented at the annual meeting of the American Diabetes Association in Chicago over the weekend that showed no safety issues in a mid-stage trial of its oral weight-loss candidate orforglipron in people with diabetes. Late-stage obesity data for orforglipron are due in the third quarter. "Novo’s status has clearly changed from being the obesity leader to a fast follower," Manns said. CagriSema is key to Novo’s efforts to compete with Lilly in the obesity market, which analysts estimate could top $150 billion annually by 2030. Novo had billed CagriSema as a more potent successor to Wegovy, but late-stage headline trial results published in December 2024 fell short of market hopes, showing 22.7% average weight loss over 68 weeks - below the company’s 25% target. That sent shares plunging, wiping as much as $125 billion off its market value. Shares, which have slumped some 55% since a June 2024 peak, are up about 8% since his departure was announced on May 16. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is LLY one of them?

Click Subscribe #NovoNordisk #CagriSema #ObesityTreatment #Investing #StockMarket

Novo Nordisk falls as CagriSema obesity data shows no clear edge vs Zepbound Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #NovoNordisk #CagriSema #Zepbound #obesity #pharmaceuticals

At #ADA2025, #CagriSema prompts us to ask, how much #WeightLoss is enough and isn't it about time to focus on health gains?
HT: @novonordisk.bsky.social
conscienhealth.org/2025/06/ada2...

#NovoNordisk has reported new data from its phase 3 programme for weight-loss therapy #CagriSema, trying to restore confidence in the drug after earlier readouts disappointed investors. #ADA

pharmaphorum.com/news/ada-nov...

Novo Nordisk réalise une percée avec son nouveau médicament amaigrissant CagriSema Principaux renseignements Le médicament expérimental pour la perte de poids CagriSema de Novo Nordisk a montré des résultats prometteurs dans les essais de phase finale, avec des effets secondaires principalement légers à modérés. Ces résultats complets ont été présentés lors de la réunion annuelle de l’American Diabetes Association et publiés dans le New England Journal […]

Novo Nordisk réalise une percée avec son nouveau médicament amaigrissant CagriSema #NovoNordisk #CagriSema #perteDePoids #médicament #santé

Novo Nordisk boekt doorbraak met nieuw afslankmedicijn CagriSema Key takeaways Het experimentele medicijn voor gewichtsverlies CagriSema van Novo Nordisk heeft veelbelovende resultaten laten zien in laat stadium onderzoek, waarbij overwegend milde tot matige bijwerkingen werden waargenomen. Deze volledige resultaten werden gepresenteerd op de jaarlijkse bijeenkomst van de American Diabetes Association en gepubliceerd in de New England Journal of Medicine. Lange termijnstudie toont overtuigend […]

Novo Nordisk boekt doorbraak met nieuw afslankmedicijn CagriSema #CagriSema #NovoNordisk #afslankmedicijn #gewichtsverlies #obesitas

🏆 Weight loss & CV

#Amycretin 💉 ⬇️23% @36w (🤢 ~65%, CV TBD)

#CagriSema 💉 ⬇️22.7% @68w (🌊 sema-like GI, CV running ❤️‍🔥)

#Zepbound 💉 ⬇️22.5% @72w (⬇️MACE ~20% 🫀)

#Wegovy 💉 ⬇️15% @68w (⬇️MACE ~20% 💓)

#Orforglipron 💊 ⬇️7.9% @40w in T2D (GLP-1 AEs)

#Retatrutide 💉 ⬇️24.2% @48w (GI TBD ⚠️)

Who wins 📉 + ❤️?

Four panels from a clinical trial show the effects of once-weekly CagriSema vs placebo in adults with type 2 diabetes and obesity. Panel A and B: Line charts show weight loss over 68 weeks with CagriSema achieving −15.7% vs −3.1% placebo. Panel C and D: Bar charts show proportions of patients achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss. CagriSema dramatically outperforms placebo, with 29% reaching ≥20% loss vs 0.2% on placebo (trial-product estimand). Confidence intervals and statistical significance (P<0.001) are reported throughout.

📉 CagriSema 2.4/2.4 mg also shows strong results in people with T2D

−15.7% mean weight loss vs −3.1% placebo at 68 weeks
💪

Combo still delivers, even with insulin resistance on board.

#CagriSema #T2D #Obesity #GLP1 #NEJM #NovoNordisk #ADA2025 #Diabetes

Bar and line charts from REDEFINE-1 show body weight change over 68 weeks for patients receiving CagriSema, semaglutide, cagrilintide, or placebo. The combination (CagriSema) leads to the greatest weight loss (−22.7%) compared with semaglutide (−16.1%), cagrilintide (−11.8%), and placebo (−2.3%). Panel A presents mean percent weight change by group; Panel B shows time-course curves of weight reduction. CagriSema consistently outperforms all other arms.

📊 CagriSema 2.4/2.4 mg just dominated in REDEFINE-1 💥💉

−22.7% mean weight loss at 68 weeks vs −2.3% placebo.

Best-in-class? Combo GLP-1 + amylin is setting new records 🚀

#CagriSema #Obesity #NEJM #NovoNordisk #ADA2025 #NVO

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #NovoNordisk #WeightLoss #CagriSema #Pharmaceuticals #ClinicalTrials

CagriSema Shatters Weight Loss Records for Obese Adults in New Studies Recent studies present CagriSema's remarkable efficacy in aiding weight loss for adults with obesity, targeting metabolism and appetite control.

CagriSema Shatters Weight Loss Records for Obese Adults in New Studies #USA #Chicago #weight_loss #diabetes #CagriSema

Novo Nordisk's CagriSema Trial Shows Promising Weight Loss Results in Obese Adults Novo Nordisk's CagriSema, tested in the REDEFINE 1 trial, achieved a significant 22.7% weight reduction in adults with obesity, marking a breakthrough in obesity treatment.

Novo Nordisk's CagriSema Trial Shows Promising Weight Loss Results in Obese Adults #USA #Novo_Nordisk #Plainsboro #CagriSema #REDEFINE

UK weight loss market: M&A opportunities Explore the latest M&A opportunities in the UK weight loss market, including market access for products like Wegovy and Mounjaro. Stay informed about key trends and opportunities in the industry.

#Obesity #GLP1receptoragonists #NovoNordisk #Wegovy #EliLilly #Mounjaro #CagriSema #Pfizer #AstraZeneca #VikingTherapeutics #VerdivaBio #Versanis #Bimagrumab #InversagoPharma #oralCB1inverseagonist #Roche #CarmotTherapeutics #NHSDigitalWeightManagementProgramme
pharmaphorum.com/market-acces...